CJC-1295 with DAC and LGD-4033 Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 with DAC and LGD-4033 have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 with DAC and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 with DAC

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..

Half-life: 6-8 days Typical dose: 1-2mg weekly growth hormone, weight loss
ghrh receptorigf1 carcinogenic riskestrogenicinsulin disrupting
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 with DAC, LGD-4033). Monitor accordingly.
2x 2 estrogenic compounds (CJC-1295 with DAC, LGD-4033). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.

Frequently Asked Questions

Can I take CJC-1295 with DAC with LGD-4033?

Yes, but with caution. Both CJC-1295 with DAC and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 with DAC and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic. Monitor accordingly.

What are the interactions between CJC-1295 with DAC and LGD-4033?

Both CJC-1295 with DAC and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 with DAC and LGD-4033?

CJC-1295 with DAC has a half-life of 6-8 days and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 with DAC vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.